Fibroblast growth factor 21 is a hepatokine involved in MASLD progression.

Rocío Gallego-DuránJavier AmpueroDouglas Maya-MilesHelena Pastor-RamírezRocío Montero-VallejoJesus Manuel Rivera EstebanLeticia Álvarez-AmorMaría Jesús ParejaMaría Carmen RicoRaquel MillánMaría José Robles-FríasRocío AllerÁngela RojasRocío Muñoz-HernándezAntonio Gil-GómezSheila GatoMaría García-LozanoMaría Teresa Arias-LosteJavier AbadJose Luis CallejaRaúl J AndradeJavier CrespoÁgueda González-RodríguezCarmelo García-MonzónFausto AndreolaJuan Manuel PericásRajiv JalanFrancisco Martín-BermudoManuel Romero-Gómez

Published in: United European gastroenterology journal (2024)

Hepatic and circulating FGF21 expression was increased in MASH patients, in Huh7.5 cells under FFAs and in CDA-HFD animals. The A-allele from the rs838133 variant was also associated with an increased risk of steatohepatitis and significant and advanced fibrosis in MASLD patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
poor prognosis
induced apoptosis
patient reported outcomes
metabolic syndrome
cell death
skeletal muscle
signaling pathway
endoplasmic reticulum stress